Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, Reed-Guy L, Bleiberg B, Sun L, Singh A, Cohen RB, Aggarwal C, Marmarelis M, Langer C. Barsouk A, et al. Among authors: cohen rb. Lung Cancer. 2024 Sep;195:107926. doi: 10.1016/j.lungcan.2024.107926. Epub 2024 Aug 10. Lung Cancer. 2024. PMID: 39137595
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, Forastiere AA; Eastern Cooperative Oncology Group. Langer CJ, et al. Among authors: cohen rb. Cancer Invest. 2004;22(6):823-31. doi: 10.1081/cnv-200039628. Cancer Invest. 2004. PMID: 15641479 Clinical Trial.
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, Nicolaou N, Sherman EJ, Babb JS, Damsker JA, Langer CJ. Kramer NM, et al. Among authors: cohen rb. Head Neck. 2005 May;27(5):406-14. doi: 10.1002/hed.20163. Head Neck. 2005. PMID: 15719391 Clinical Trial.
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Borghaei H, et al. Among authors: cohen rb. J Clin Oncol. 2009 Sep 1;27(25):4116-23. doi: 10.1200/JCO.2008.20.2515. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636016 Free PMC article. Clinical Trial.
Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial.
Bauml J, Haas A, Simone CB 2nd, Li SQ, Cohen RB, Langer CJ, Mao JJ. Bauml J, et al. Among authors: cohen rb. Integr Cancer Ther. 2016 Sep;15(3):326-32. doi: 10.1177/1534735415624138. Epub 2016 Apr 24. Integr Cancer Ther. 2016. PMID: 27114385 Free PMC article.
354 results